Clik here to view.
欧州委員会が武田薬品のALUNBRIG®（ブリガチニブ）をALK+ NSCLCのファーストライン治療薬として承認
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Announce Global License, Development and...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TOKYO: 4151) today jointly announced that the companies have entered into a global license, development...
View ArticleClik here to view.
JCI MN COLLOIDAL IODINE® (IMS Tokyo, Japan) May Have Marked Efficacy Against...
TOKYO Iodine, known for its potent antibacterial effects, has been in use in a variety of formulations, particularly to disinfect skin and mucosa. However, iodine is an irritant that cannot be...
View ArticleClik here to view.
Propanc Biopharma Receives First Allowance for Key Patent Family from...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC:PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with...
TORONTO & SINGAPORE Cyclica announces a multi-year and multi-project collaboration with the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and...
View ArticleClik here to view.
Hansoh Expands AI Partnership with Atomwise after Early Success for Key...
SHANGHAI & SAN FRANCISCO Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the...
View ArticleClik here to view.
Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb) for...
INCHEON, Korea Samsung Bioepis Co., Ltd. announced today that ONTRUZANT® (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN®1 (trastuzumab) for the treatment of...
View ArticleClik here to view.
How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research...
DAEJEON, South Korea LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080), based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda...
View ArticleClik here to view.
Genetron Health Announces Forthcoming Unveiling of Its Cancer Research Papers...
BEIJING Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that 14 cancer research papers will be presented as...
View ArticleClik here to view.
Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover...
FOSTER CITY, Calif. & SANTA MONICA, Calif. & MELBOURNE, Australia Gilead Sciences, Inc. (Nasdaq: GILD), Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a...
View ArticleClik here to view.
NEC Publishes Design Blueprints for SARS-CoV-2 Vaccines Using Its Artificial...
TOKYO NEC Corporation (NEC; TOKYO: 6701) today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell...
View ArticleClik here to view.
EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce...
SHANGHAI & BRISBANE, Australia EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and the QIMR Berghofer Medical Research...
View ArticleClik here to view.
NEC发布采用其人工智能技术的SARS-CoV-2疫苗设计蓝图
东京 (美国商业资讯)–NEC Corporation (NEC; TOKYO: 6701)今天发布采用AI预测平台设计SARS-CoV-2疫苗蓝图的分析结果，该疫苗能在全球多数人群中推动强效T细胞应答。NEC集团科学团队发起的这项创举旨在帮助抗击COVID-19疫情并支持国际疫苗开发努力，由NEC OncoImmununity (NOI)与NEC Laboratories Europe...
View ArticleClik here to view.
Takeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core over-the-counter...
View ArticleClik here to view.
Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy...
View ArticleClik here to view.
武田宣布mobocertinib (TAK-788)获美国FDA突破性治疗药物认证，用于治疗EGFR外显子20插入突变型NSCLC患者
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，其在研药物mobocertinib...
View ArticleClik here to view.
武田薬品、米国FDAがEGFRエクソン20挿入変異を伴うNSCLC患者を治療するmobocertinib （TAK-788）を画期的治療薬に指定したと発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing...
LOS ANGELES Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital...
View ArticleClik here to view.
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA®...
TEL AVIV, Israel & PARSIPPANY, N.J. & INCHEON, South Korea Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion...
View Article